{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T08:01:36Z","timestamp":1780128096936,"version":"3.54.0"},"reference-count":23,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"DOI":"10.13039\/501100009601","name":"Beijing Municipal Administration of Hospitals","doi-asserted-by":"publisher","award":["YGLX202537"],"award-info":[{"award-number":["YGLX202537"]}],"id":[{"id":"10.13039\/501100009601","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Therapeutic Advances in Psychopharmacology"],"published-print":{"date-parts":[[2026,5]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>The potential of aripiprazole to reverse amisulpride-induced hyperprolactinemia has yet to be established.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives:<\/jats:title>\n                    <jats:p>To investigate whether adjunctive aripiprazole treatment can reverse amisulpride-induced prolactin (PRL) elevation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design:<\/jats:title>\n                    <jats:p>This study was a single-arm retrospective cohort study.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>\n                      We conducted a retrospective analysis of medical records from patients treated with amisulpride at a tertiary specialized psychiatric hospital, between June 1, 2022, and December 31, 2025, who subsequently received adjunctive aripiprazole. Data were collected via the electronic medical record system. A paired\n                      <jats:italic toggle=\"yes\">t<\/jats:italic>\n                      -test was used to compare PRL values before (\u2a7d7\u2009days, PRL1) and after (\u2a7e7\u2009days, PRL2) aripiprazole initiation.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      The difference between PRL1 and PRL2 was not statistically significant (mean difference\u2009=\u20094.115\u2009ng\/ml, 95% CI (\u22125.121, 13.351) ng\/ml, SD\u2009=\u200915.284,\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      \u2009=\u20090.351, Cohen\u2019s\n                      <jats:italic toggle=\"yes\">d<\/jats:italic>\n                      \u2009=\u20090.269, 95% CI for\n                      <jats:italic toggle=\"yes\">d<\/jats:italic>\n                      (\u22120.290, 0.818)). Stratified analyses by sex and diagnosis yielded results consistent with the main analysis across subgroups (\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      \u2009&gt;\u20090.05). None of the leave-one-out analyses altered the study\u2019s conclusions (all\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      -values\u2009&gt;\u20090.05), indicating that the results were not driven by any single extreme value.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>In individuals with amisulpride-related hyperprolactinemia, this retrospective study suggests that adjunctive aripiprazole has an insignificant therapeutic effect in reversing PRL elevation. Therefore, until more comprehensive research evidence becomes available, a cautious approach should be taken in clinical practice regarding the use of adjunctive aripiprazole to reverse amisulpride-induced PRL elevation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/20451253261450772","type":"journal-article","created":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T13:06:57Z","timestamp":1779887217000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Adjunctive aripiprazole for amisulpride-induced hyperprolactinemia: a preliminary retrospective study showing no reversing effect"],"prefix":"10.1177","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-6938-6152","authenticated-orcid":false,"given":"Xiaoqian","family":"Lan","sequence":"first","affiliation":[{"name":"Beijing Key Laboratory of Intelligent Drug Research and Development for Mental Disorders, National Clinical Research Center for Mental Disorders, National Center for Mental Disorders, Beijing Anding Hospital, Capital Medical University, Beijing, China"},{"name":"Beijing Key Laboratory of Critical Bridging Technologies for Chronic Disease Drug Development"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongyan","family":"Zhuang","sequence":"additional","affiliation":[{"name":"Beijing Key Laboratory of Intelligent Drug Research and Development for Mental Disorders, National Clinical Research Center for Mental Disorders, National Center for Mental Disorders, Beijing Anding Hospital, Capital Medical University, Beijing, China"},{"name":"Beijing Key Laboratory of Critical Bridging Technologies for Chronic Disease Drug Development"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pengfei","family":"Li","sequence":"additional","affiliation":[{"name":"Beijing Key Laboratory of Intelligent Drug Research and Development for Mental Disorders, National Clinical Research Center for Mental Disorders, National Center for Mental Disorders, Beijing Anding Hospital, Capital Medical University, 5 Ankang Hutong, Deshengmenwai Avenue, Xicheng District, Beijing 100088, China"},{"name":"Beijing Key Laboratory of Critical Bridging Technologies for Chronic Disease Drug"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,5,27]]},"reference":[{"key":"e_1_3_4_2_2","first-page":"1","article-title":"Clinical outcomes and serum prolactin levels in patients with antipsychotic-induced hyperprolactinemia following different management strategies","volume":"24","author":"Sangngarm A","year":"2025","unstructured":"Sangngarm A, Werawattanachai C, Somrak K, et al. Clinical outcomes and serum prolactin levels in patients with antipsychotic-induced hyperprolactinemia following different management strategies. Int J Psychiatry Clin Pract 2025; 24: 1\u20137.","journal-title":"Int J Psychiatry Clin Pract"},{"key":"e_1_3_4_3_2","first-page":"421","article-title":"The effects of novel and newly approved antipsychotics on serum prolactin levels: a comprehensive review","volume":"28","author":"Peuskens J","year":"2014","unstructured":"Peuskens J, Pani L, Detraux J, et al. The effects of novel and newly approved antipsychotics on serum prolactin levels: a comprehensive review. CNS Drugs 2014; 28: 421\u2013453.","journal-title":"CNS Drugs"},{"key":"e_1_3_4_4_2","doi-asserted-by":"publisher","DOI":"10.1177\/0269881107088435"},{"key":"e_1_3_4_5_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-2003-39764"},{"key":"e_1_3_4_6_2","first-page":"320","article-title":"Normalization of hyperprolactinaemia after withdrawal of a low dose of amisulpride","volume":"26","author":"Kopecek M","year":"2005","unstructured":"Kopecek M, Bares M, Hor\u00e1cek J. Normalization of hyperprolactinaemia after withdrawal of a low dose of amisulpride. Neuro Endocrinol Lett 2005; 26: 320.","journal-title":"Neuro Endocrinol Lett"},{"key":"e_1_3_4_7_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-025-01218-z"},{"key":"e_1_3_4_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.encep.2012.03.002"},{"key":"e_1_3_4_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.pnpbp.2006.07.006"},{"key":"e_1_3_4_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.yfrne.2017.02.003"},{"key":"e_1_3_4_11_2","doi-asserted-by":"publisher","DOI":"10.1111\/bcpt.13323"},{"key":"e_1_3_4_12_2","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.60.7.681"},{"issue":"8","key":"e_1_3_4_13_2","article-title":"Adjunctive aripiprazole versus placebo for antipsychotic-induced hyperprolactinemia: meta-analysis of randomized controlled trials","volume":"8","author":"Li X","year":"2013","unstructured":"Li X, Tang Y, Wang C. Adjunctive aripiprazole versus placebo for antipsychotic-induced hyperprolactinemia: meta-analysis of randomized controlled trials. PLoS One 2013; 8(8): e70179.","journal-title":"PLoS One"},{"issue":"1","key":"e_1_3_4_14_2","first-page":"4","article-title":"Using aripiprazole to reduce antipsychotic-induced hyperprolactinemia: meta-analysis of currently available randomized controlled trials","volume":"27","author":"Meng M","year":"2015","unstructured":"Meng M, Li W, Zhang S, et al. Using aripiprazole to reduce antipsychotic-induced hyperprolactinemia: meta-analysis of currently available randomized controlled trials. Shanghai Arch Psychiatry 2015; 27(1): 4\u201317.","journal-title":"Shanghai Arch Psychiatry"},{"key":"e_1_3_4_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2020.04.031"},{"key":"e_1_3_4_16_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41398-022-02027-4"},{"key":"e_1_3_4_17_2","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2024.1337274"},{"key":"e_1_3_4_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2025.04.011"},{"key":"e_1_3_4_19_2","doi-asserted-by":"publisher","DOI":"10.1017\/S1461145706007115"},{"key":"e_1_3_4_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(07)61602-X"},{"key":"e_1_3_4_21_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-004-1826-6"},{"key":"e_1_3_4_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0028-3908(96)00100-1"},{"key":"e_1_3_4_23_2","article-title":"Prolactin elevations and permeability glycoprotein","volume":"21","author":"El-Mallakh RS","year":"2019","unstructured":"El-Mallakh RS, Watkins J. Prolactin elevations and permeability glycoprotein. Prim Care Companion CNS Disord 2019; 21: 18nr02412.","journal-title":"Prim Care Companion CNS Disord"},{"key":"e_1_3_4_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.pnpbp.2010.08.012"}],"container-title":["Therapeutic Advances in Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/20451253261450772","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/20451253261450772","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/20451253261450772","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T07:20:53Z","timestamp":1780125653000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/20451253261450772"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":23,"alternative-id":["10.1177\/20451253261450772"],"URL":"https:\/\/doi.org\/10.1177\/20451253261450772","relation":{},"ISSN":["2045-1253","2045-1261"],"issn-type":[{"value":"2045-1253","type":"print"},{"value":"2045-1261","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5]]},"article-number":"20451253261450772"}}